【摘要】 目的　客观评价肾移植术后骁悉 (mycohpenolatemofetil ,MMF)与硫唑嘌呤 (azathioprine ,AZA)抗排斥反应效果的差别。　方法　计算机检索Medline (1996～ 2 0 0 2 .6 )、Embase (1984～ 2 0 0 2 .6 )、Cochrane图书馆 (2 0 0 2年第二期 )及中国生物医学文献数据库 (1979～ 2 0 0 2 .6 ) ,鉴定有关随机对照试验 ,并采用Revman 4 .11进行Meta 分析。　结果　共纳入 2 2个随机对照试验 ,涉及不同剂量MMF与AZA用于肾移植术后抗排斥治疗 ,发现MMF 2 g/d比AZA可提高移植肾短期存活率及病人长期存活率 ,而MMF3g/d与AZA对提高病人及移植肾存活率无统计学差异。术后 6月至 1年内 ,MMF 2 g/d或MMF 3g/d均较AZA明显降低移植肾急性排斥发生率。　结论　MMF较AZA免疫抑制效力更强 ,MMF降低肾移植术后急性排斥反应发生率明显优于AZA ,运用MMF对提高肾移植术后移植肾存活率及病人长期生存率有利。MMF 2 g/d是较理想的使用剂量。更多还原

【Abstract】 Objective To evaluate the efficacy of mycophenolate Mofetil (MMF) and azathioprine (AZA) after renal transplantation. Methods Searching: Medline, Embase, Cochrane library an d Chinese Biomedicine database (CBM); identified the randomized controlled trials (RCTs) and applied Revman 4.11 for statistical analyses. Results Twenty-two RCTs were identified, involving MMF and AZA for anti-rej ection after renal transplantation. The data shown that MMF (2 g/d) was more ben eficial than AZA in improving the graft survival rate of short periods and the l ong-term patient survival rate, but there was no statistical differences betwee n MMF (3 g/d) with AZA. Whether in 6 months or in 1 year after renal transplanta tion, the use of MMF (2 g/d) or MMF (3 g/d) could markedly reduce the incidence of biopsy-proven rejection. Conclusion Comparing with A ZA, MMF is a more potent immunosuppressive drug, and more efficient in reducing the acute rejection after renal transplantation. MMF can improve the graft and p atient survival rate. The 2 gram per day is more acceptable.更多还原